In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer PatientsMaria Vassilakopoulou, Amanda Psyrri, Jennifer Bordeaux et al.|PLoS ONE|2014Cited by 27
In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.Maria Vassilakopoulou, Amanda Psyrri, Jennifer Bordeaux et al.|Journal of Clinical Oncology|2012Cited by 0